Physician profile
Mark B Braunstein
NPI 1598788754
$6,971.56
in general payments reported to CMS, 2019-2025
44 companies · $1,081 in 2025
The $1,081 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $367 · 2020: $926 · 2021: $1,399 · 2022: $1,233 · 2023: $812 · 2024: $1,154 · 2025: $1,081.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,047.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,046.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,704.90 | 2021-2025 | Vraylar, Qulipta |
| Amgen INC. | $878.41 | 2019-2025 | Repatha, Otezla, Repatha |
| Allergan, INC. | $552.51 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $515.80 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Bausch Health US, LLC | $311.47 | 2020-2025 | Aplenzin, Wellbutrin |
| Otsuka America Pharmaceutical, INC. | $297.61 | 2021-2025 | Rexulti, Abilify Maintena |
| Lilly USA, LLC | $295.92 | 2019-2025 | Zepbound, Mounjaro, Emgality |
| Bayer Healthcare Pharmaceuticals INC. | $268.30 | 2022-2025 | |
| Sunovion Pharmaceuticals INC. | $240.54 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $222.77 | 2019-2024 | Trintellix |
| Novo Nordisk INC | $222.05 | 2021-2025 | Rybelsus, Ozempic, Saxenda |
| Collegium Pharmaceutical, INC. | $191.37 | 2020-2023 | Belbuca |
| Paratek Pharmaceuticals, INC. | $141.09 | 2020-2024 | Nuzyra |
| Biohaven Pharmaceutical Holding Company LTD. | $92.72 | 2022 | |
| Pfizer INC. | $92.22 | 2021-2025 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Braunstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.